Leuprolide: Lupron/Eligard, hormone-shutdown drug for cancer & reproductive conditions
A synthetic hormone drug that shuts off the body's testosterone or estrogen production; FDA-approved for prostate cancer, endometriosis, uterine fibroids, and early puberty in children.
- Class
- GnRH agonist (synthetic nonapeptide)
- Status
- FDA-approved prescription drug (since April 1985); approved internationally (EMA, MHRA, Health Canada, TGA, Japan, China)
- Best-supported effect
- Profound gonadal hormone suppression in adults with advanced prostate cancer, in adults with endometriosis-associated pain or uterine fibroids (preoperative), and in children with central precocious puberty
- Main caveat
- Sustained suppression carries known consequences — initial testosterone "flare," progressive bone mineral density loss with extended use, and cardiovascular risk signals during long-term androgen deprivation
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Leuprolide (sold as Lupron Depot and Eligard) is an injectable medication that treats hormone-sensitive cancers and conditions by shutting off the body's production of testosterone or estrogen. It is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids (before surgery), and a condition in children called central precocious puberty. It has been in continuous clinical use since its first FDA approval in April 1985 — one of the most established peptide therapeutics in medicine. The drug is a synthetic analog of a natural pituitary hormone called GnRH (gonadotropin-releasing hormone); its key structural changes — a D-leucine substitution at position 6 and a Pro-ethylamide cap at the C-terminus — give it far greater potency and metabolic stability than the native hormone, and make possible the long-acting depot formulations (monthly, 3-month, 4-month, and 6-month injections) that define its clinical use. The stored raw sequence PHWSYLLR is a partial representation of the backbone; the full 9-residue sequence also includes an N-terminal pyroglutamate and the D-Leu at position 6, neither of which appear in the stored 8-letter form.
History
The foundation for leuprolide was laid in the early 1970s when Andrew Schally and Roger Guillemin independently isolated and characterized native GnRH (also called LHRH) — work recognized by the 1977 Nobel Prize in Physiology or Medicine. The insight that transformed prostate cancer treatment was paradoxical: whereas native GnRH is released in pulses to sustain LH and FSH secretion, continuous stimulation with a potent analog causes the very opposite — pituitary desensitization and hormone shutdown. Schally's group and others identified the structural modifications that enhanced potency and metabolic stability, particularly D-amino acid substitution at position 6 and C-terminal ethylamide. Leuprolide (D-Leu6, des-Gly10, Pro-NHEt-GnRH) was developed by Abbott Laboratories and received FDA approval in April 1985 as Lupron Depot for advanced prostate cancer, replacing surgical orchiectomy as the primary form of androgen deprivation therapy (Fontana et al. 2021). Approval subsequently expanded to endometriosis (1990), central precocious puberty (1993), and uterine fibroids (1995). Depot formulations using PLGA microsphere and polymer-implant technology enabled sustained release, dramatically improving adherence over daily injection. Subsequent GnRH agonists (goserelin, triptorelin, histrelin) and the later GnRH antagonist class (degarelix injectable, oral relugolix) compete in the same therapeutic space.
What it does
Leuprolide works by overwhelming — and ultimately silencing — the hormonal control system that governs testosterone and estrogen production. Normally the brain sends GnRH signals in pulses to the pituitary gland, which then releases LH and FSH to stimulate the gonads. When leuprolide is given continuously at pharmacologic doses, the pituitary's GnRH receptors are flooded with a constant, non-pulsatile signal. Rather than amplifying hormone output, this causes the receptors to shut down through a process called desensitization and downregulation. Within three to four weeks, LH and FSH levels fall sharply, and the gonads stop producing sex hormones — an effect called medical castration. In men with prostate cancer this removes the androgen fuel that drives tumor growth; in women with endometriosis or uterine fibroids it temporarily induces a low-estrogen state that reduces pain and fibroid size; in children with central precocious puberty it halts inappropriately early sexual development and protects normal adult height (Fontana et al. 2021; Vannuccini et al. 2022).
There is an important counter-intuitive effect in the first one to two weeks: before desensitization takes hold, the initial stimulation causes a transient "flare" in which testosterone or estrogen briefly rises. In prostate cancer patients with high tumor burden, this flare can temporarily worsen bone pain or other symptoms, and is managed in clinical practice by pre-treating with an anti-androgen for the first two to four weeks.
Evidence
- Human: Extensive. FDA-approved across four indications since 1985, supported by decades of randomized controlled trials, meta-analyses, and post-marketing pharmacovigilance. Key trials include EMBARK (enzalutamide ± leuprolide in high-risk biochemically recurrent prostate cancer — improved metastasis-free survival with combination), NRG/RTOG 9408 (short-term ADT plus radiation vs radiation alone in localized prostate cancer — long-term survival benefit confirmed), PRONOUNCE (leuprolide vs degarelix in prostate cancer patients with cardiovascular disease — primary cardiovascular endpoint inconclusive), and HERO (leuprolide vs oral relugolix — relugolix achieved faster testosterone recovery and favored in some cardiovascular subgroups) (Fontana et al. 2021; Vannuccini et al. 2022). A meta-analysis of the 11.25 mg 3-month leuprolide formulation in children with central precocious puberty confirmed effective LH suppression and preservation of predicted adult height comparable to triptorelin pamoate.
- Animal: Strong. GnRH receptor desensitization and downregulation under continuous agonist exposure are thoroughly characterized in animal models; forms the mechanistic basis for clinical use.
- In vitro: Strong. GnRH receptor pharmacology, receptor internalization, and Gq-signaling uncoupling are well-defined at the molecular level.
Known effects
- Medical castration (testosterone <50 ng/dL) in advanced prostate cancer — FDA-approved; Phase III RCT evidence across multiple trials
- Reduction of endometriosis-associated pelvic pain — FDA-approved; Phase III RCT and meta-analysis evidence (Vannuccini et al. 2022)
- Preoperative uterine fibroid size reduction — FDA-approved
- Suppression of pubertal progression in central precocious puberty — FDA-approved; meta-analysis evidence
- LH/FSH suppression for pituitary down-regulation in assisted reproduction (IVF) — Widely used off-label; RCT evidence for dual-trigger protocols
- Bone mineral density loss with extended use — Expected pharmacologic consequence; progressive without intervention; requires active management
- Hot flashes, decreased libido, mood changes, fatigue — Expected consequence of sex-hormone suppression; documented across trials
Safety signals
Bone mineral density loss is the most clinically significant chronic consequence of extended ADT — substantial, predictable, and progressive without intervention; fracture risk increases meaningfully with prolonged use (Fontana et al. 2021). Baseline DXA, calcium and vitamin D supplementation, and consideration of bisphosphonate or denosumab therapy are part of established clinical management for extended ADT.
The initial testosterone or estrogen "flare" during the first one to two weeks can transiently worsen bone-metastasis pain, ureteral obstruction, or spinal cord compression risk in prostate cancer patients with high tumor burden; anti-androgen pre-loading (bicalutamide, flutamide) is standard practice for the first two to four weeks.
Cardiovascular risk during long-term androgen deprivation is a recognized association. The PRONOUNCE trial (degarelix vs leuprolide in patients with pre-existing cardiovascular disease) was inconclusive on the primary cardiovascular endpoint; the HERO trial data have driven interest in GnRH antagonists (degarelix, relugolix) in some high-risk cardiovascular subgroups.
Additional signals documented across label and trials: hot flashes, decreased libido, erectile dysfunction, mood changes, fatigue and cognitive complaints, QT-interval prolongation (ECG and electrolyte monitoring appropriate in patients with relevant risk factors), and pregnancy/fetal harm (effective contraception required during therapy and for a period after discontinuation).
Leuprolide has a limited classical drug-interaction profile because peptide proteolytic clearance does not engage CYP-mediated metabolism. Clinically relevant interactions are largely pharmacodynamic: intentional co-administration with anti-androgens (bicalutamide, flutamide, enzalutamide) is standard practice during the flare period and as combined androgen blockade; the EMBARK trial defines expanded combined-blockade indications.
Regulatory status
- US (FDA): Prescription-only. Initial approval April 1985 (Lupron Depot) for advanced prostate cancer; subsequent approvals for endometriosis (1990), central precocious puberty (1993), and uterine fibroids — preoperative (1995). Multiple branded formulations (Lupron, Lupron Depot, Eligard) and generics available across 1-, 3-, 4-, and 6-month depot intervals. Not a controlled substance.
- EU / International: Approved across major markets (EMA, MHRA, Health Canada, TGA, Japan, China) for similar indications. Multiple generic depot formulations available worldwide. Class alternatives include goserelin (Zoladex), triptorelin (Decapeptyl), histrelin (Vantas/Supprelin LA), and the oral GnRH antagonist relugolix (Orgovyx).
- WADA: Prohibited at all times in male athletes under S4 (Hormone and Metabolic Modulators). Therapeutic use for approved indications with appropriate Therapeutic Use Exemption is permitted; non-therapeutic use is prohibited in and out of competition.
Myths and misconceptions
- "Leuprolide raises testosterone — it stimulates the GnRH receptor." The opposite is true in sustained use. An initial one-to-two-week stimulatory flare is followed by GnRH receptor desensitization and downregulation, producing castrate-level testosterone within three to four weeks. Depot formulations exist precisely to maintain the continuous suppressive signal. Anyone using it expecting sustained testosterone elevation is misreading the pharmacology.
- "GnRH agonists can safely restart testosterone production after anabolic steroid use." This is a claim circulating in wellness and bodybuilding forums and lacks controlled-trial evidence. Even short-course GnRH agonist exposure can produce prolonged HPG-axis suppression rather than the intended restart. This off-label use is not supported by data and carries risk of unintended chronic suppression.
- "Leuprolide's effects are permanent." GnRH agonist effects are reversible in most patients. Testosterone recovery after discontinuation typically takes six to twelve months or longer and may be incomplete in older men after extended ADT; in premenopausal women treated for endometriosis or fibroids, menstrual cycles generally resume within one to six months.
- "Bone loss on ADT is a minor concern." ADT-induced bone loss is substantial, predictable, and clinically meaningful — fracture risk increases with extended use. Active management (baseline DXA, supplementation, and consideration of bisphosphonate or denosumab) is part of the standard of care for extended ADT, not an optional adjunct (Fontana et al. 2021).
Open questions
- GnRH agonist vs antagonist comparative cardiovascular outcomes: PRONOUNCE (degarelix vs leuprolide) was inconclusive on its primary cardiovascular endpoint; optimal selection in patients with pre-existing cardiovascular disease remains debated.
- Optimal duration of adjuvant ADT with definitive radiation in localized prostate cancer: High-risk disease typically receives 24–36 months, but optimal duration in intermediate-risk disease and the role of adding second-generation anti-androgens (apalutamide, enzalutamide) is evolving.
- Bone-health management protocols during extended ADT: Bisphosphonate, denosumab, and SERM approaches are all used; comparative effectiveness and patient-selection algorithms are imperfect.
- Intermittent vs continuous ADT: Multiple large trials suggest intermittent ADT is non-inferior for some endpoints with quality-of-life benefit, but practice patterns and patient-selection criteria remain inconsistent.
- Endometriosis treatment beyond 12 months: The labeled limit is 12 months with hormonal add-back; longer-duration use is sometimes clinically necessary but lacks strong trial support (Vannuccini et al. 2022).
- Cognitive and mood effects of long-term ADT: Recognized signal for fatigue, cognitive complaints, and depression risk, but biological mechanisms and effective interventions are incompletely characterized.
Mechanism
Leuprolide is a GnRH superagonist (D-Leu6, des-Gly10, Pro-NHEt-GnRH) reported as roughly 80× more potent than native GnRH. It binds the GnRH receptor on pituitary gonadotropes. Native GnRH signals in a pulsatile pattern that maintains LH and FSH secretion through Gq-coupled signaling; continuous agonist exposure instead causes receptor internalization and downregulation, uncoupling from Gq signaling. The result is a brief initial flare of LH/FSH and consequent sex-steroid rise during the first 7–14 days, followed by pituitary desensitization over the next 2–4 weeks and medical-castration-level testosterone (below 50 ng/dL, with current consensus favoring below 20 ng/dL for optimal oncologic outcome) by week 3–4. Estrogen suppression follows a similar timeline in premenopausal women treated for endometriosis or fibroids. After discontinuation, pituitary recovery and gonadal function typically return slowly: testosterone recovery to baseline can take 6–12 months or longer after extended ADT and may be incomplete in older men; menstrual cycles in premenopausal women generally resume within 1–6 months (Fontana et al. 2021).
Related peptides
- Gonadorelin — the synthetic form of native GnRH, given in pulsatile fashion to stimulate rather than suppress the HPG axis; the pharmacologic opposite of continuous leuprolide use.
- Goserelin — another GnRH agonist in the same class as leuprolide, available as a subcutaneous implant (Zoladex); similar mechanism and indications but different depot delivery format.
- Triptorelin — GnRH agonist class; used for prostate cancer, endometriosis, and precocious puberty; direct comparator to leuprolide in some pediatric endocrinology studies.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does leuprolide need to stay above a certain blood concentration to keep working, and does its effect drop off sharply rather than slowly when levels dip?
If a sharp threshold exists, doctors could aim for a precise minimum blood level with long-acting injections, which might reduce the testosterone rebound that some patients on these formulations experience.
Does leuprolide act directly on endometriosis lesions to break them down, separate from its effect of stopping ovulation?
If leuprolide works directly on lesions at lower doses, women with endometriosis who want to conceive might be treated without the months-long fertility delay that full hormone suppression currently causes.
Does leuprolide act on hormone receptors in the brain to reduce the kind of inflammation thought to contribute to Alzheimer's disease?
If supported, a drug already used safely for decades could be studied in older adults at risk for Alzheimer's, offering a head start on prevention research with an already-approved medication.
Does leuprolide act on tumor cells themselves through a second signaling route, separate from lowering testosterone?
If a direct effect on tumor cells is confirmed, men whose prostate cancer has stopped responding to hormone suppression might still get some benefit from continued treatment, giving oncologists an option to study when current therapy fails.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.9029234647750854 | boltz-2 |
| ranking score | 0.7846274375915527 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.648 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep04422,
sequence = {PHWSYLLR},
target = {gnrhr},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}